home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

964 rows where filing_year = 2016 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, is_termination, received_date (date)

filing_period 4

  • fourth_quarter 245
  • third_quarter 245
  • second_quarter 242
  • first_quarter 232

issue_code 1

  • PHA · 964 ✖

filing_year 1

  • 2016 · 964 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1802283 BOCKORNY GROUP, INC. d92ed2b6-aa21-4fe6-9ede-9f216a7226cb 1T BOCKORNY GROUP, INC. 289773 GENERIC PHARMACEUTICAL ASSOCIATION 2016 first_quarter PHA Issues Related to Biosimilar Regulation, Labeling, E-Labeling and Access Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 1 2016-02-02T11:59:12.727000-05:00
1802389 MARTA AGUIRRE BASCOM cfef6b65-cc4f-4545-85e9-2f881199e3c9 1T MARTA AGUIRRE BASCOM 307411 THE NATIONAL RETIREE LEGISLATIVE NETWORK 2016 first_quarter PHA Support for importation of prescription drugs from Canada; competitive bidding for pharmaceuticals through Medicare. HOUSE OF REPRESENTATIVES,SENATE 15000   0 1 2016-03-21T13:46:16.893000-04:00
1803011 NELSON MULLINS RILEY & SCARBOROUGH c0ce498c-c145-49e2-af0d-f83223f4fbf1 Q1 NELSON MULLINS RILEY & SCARBOROUGH 285871 INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) 2016 first_quarter PHA Any legislation and regulation to the treatment of opioid abuse. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-04-05T11:02:35.047000-04:00
1804461 NAHIGIAN STRATEGIES, LLC 49d733ec-7535-45fd-bd93-fa6dace6cd3e Q1 NAHIGIAN STRATEGIES, LLC 322897 TEVA PHARMACEUTICALS USA INC 2016 first_quarter PHA Advocate for pathway to improving existing therapies.   45000   0 0 2016-04-11T09:56:06.933000-04:00
1804653 PARRY, ROMANI, DECONCINI & SYMMS ee8d3055-d501-4081-990e-55e3053ee944 Q1 PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2016 first_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 18000   0 0 2016-04-11T12:05:13.997000-04:00
1804761 KATE MOSS d3279a37-3222-4a09-b721-72ab7760d58f Q1 KATE MOSS 25988 CVS HEALTH 2016 first_quarter PHA Issues related to prescription drug abuse and drug supply chain safety. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-04-11T14:22:54.557000-04:00
1804908 CARD & ASSOCIATES, LLC cb3c5a80-0ec3-4529-bbf5-f5bd48a12ba5 Q1 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2016 first_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2016-04-11T16:05:11.117000-04:00
1804909 CARD & ASSOCIATES, LLC 76f175ff-9604-4c6f-ae57-8a4569d1d75c Q1 CARD & ASSOCIATES, LLC 84217 CLOAKROOM ADVISORS LLC ON BEHALF OF LINDEN CARE LLC 2016 first_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2016-04-11T16:07:13.117000-04:00
1804961 DENTONS US LLP 2973adf9-03ff-4f09-990b-7443156efe34 Q1 DENTONS US LLP 36105 PHRMA 2016 first_quarter PHA HR 9 and other legislation regarding patent law reform and treatment of pharmeceuticals HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-04-11T17:03:18.047000-04:00
1804969 TCH GROUP, LLC 3e2b14e5-6f44-4795-b35f-68cb8a33600b Q1 TCH GROUP, LLC 51478 CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2016 first_quarter PHA S.483, Ensuring Patient Access and Effective Drug Enforcement Act of 2015 SENATE 20000   0 0 2016-04-11T17:35:31.027000-04:00
1805129 CHRISTY ELLERBEE CONSULTING, LLC 1311acbd-1a38-4f21-8e6c-e8003028555a 1T CHRISTY ELLERBEE CONSULTING, LLC 401103332 INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.) 2016 first_quarter PHA H.R. 2872 Opioid Addiction Treatment Modernization Act. H.R. 1821 and S. 707 Opioid Overdose Reduction Act of 2015. H.R. 2536 and S. 1455 TREAT ACT. HOUSE OF REPRESENTATIVES,SENATE     0 1 2016-04-12T10:19:29.280000-04:00
1805311 WAXMAN STRATEGIES 3a518805-40f8-4a60-a5b8-d1a748006883 Q1 WAXMAN STRATEGIES 401103693 340B HEALTH 2016 first_quarter PHA Laws and regulations affecting the 340B Drug Discount Program Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES 18750   0 0 2016-04-12T12:35:13.297000-04:00
1805341 NELSON MULLINS RILEY & SCARBOROUGH 2de2906e-1bd6-4ebf-8530-1097b76e5b99 Q1 NELSON MULLINS RILEY & SCARBOROUGH 285871 CASCADE HEMOPHILIA CONSORTIUM 2016 first_quarter PHA Issues related to 340B Drug Pricing Progam HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-04-12T13:12:11.533000-04:00
1805344 NELSON MULLINS RILEY & SCARBOROUGH 7f17808f-9a88-4b53-bdf8-5ae5ad891b25 Q1 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2016 first_quarter PHA Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-04-12T13:13:13.347000-04:00
1805402 HOLLAND & KNIGHT LLP 56e74afd-3300-48a3-9a0c-0413f3586af5 Q1 HOLLAND & KNIGHT LLP 18466 THE BIOSIMILARS FORUM 2016 first_quarter PHA Medicare reimbursement issues, FDA regulation of biosimilars. HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2016-04-12T14:08:24.290000-04:00
1805404 HOLLAND & KNIGHT LLP 03f25f92-793d-4b4b-b7e4-aa101dedae3a Q1 HOLLAND & KNIGHT LLP 18466 PROTECTING ACCESS TO PAIN RELIEF COALITION 2016 first_quarter PHA Advocating for policy to ensure patient access to pain relief. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-04-12T14:09:26.243000-04:00
1805448 ROCK & ASSOCIATES 7b1d53cc-c55f-404d-a9a8-4bf89d156f00 Q1 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2016 first_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-04-12T14:26:04.387000-04:00
1805457 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 1a4dbf74-eab7-459c-96fb-8579dd9ada8e Q1 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2016 first_quarter PHA issues related to the 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-04-12T14:29:15.183000-04:00
1805463 ROCK & ASSOCIATES c4e7f82d-452c-470e-baf2-3d90df3c7fe9 Q1 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2016 first_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-04-12T14:31:22.933000-04:00
1805472 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. f7114d59-50f2-4944-9514-9513a08d08c3 Q1 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2016 first_quarter PHA HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2016-04-12T14:34:31.667000-04:00
1805481 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 0d8b4b36-c121-49f9-a273-560f782f738b Q1 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2016 first_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2016-04-12T14:36:34.793000-04:00
1805488 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 17e76074-b95c-4e90-8b7a-911643488192 Q1 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2016 first_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 1600, Patients Access to Treatment Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE 50000   0 0 2016-04-12T14:38:38.027000-04:00
1805508 ROCK & ASSOCIATES b18b7eff-1c16-44c6-b968-9677553c4e05 Q1 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2016 first_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-04-12T14:49:00.547000-04:00
1805516 ROCK & ASSOCIATES b305fa16-79a1-4f4d-a0bc-92cce935e52e Q1 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2016 first_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-04-12T14:52:11.593000-04:00
1805521 ROCK & ASSOCIATES ad13df8b-2477-4000-ad66-456acdc487d6 Q1 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2016 first_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-04-12T14:54:19.407000-04:00
1805535 ROCK & ASSOCIATES 363c7b0d-83ff-4354-8473-19e03bcd716e Q1 ROCK & ASSOCIATES 33545 TOWN & COUNTRY COMPOUNDING AND CONSULTING 2016 first_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE     0 0 2016-04-12T14:59:36.093000-04:00
1805543 ROCK & ASSOCIATES 4d8f72b1-68ba-4b8d-a62b-bb6f6b22d563 Q1 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2016 first_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-04-12T15:04:46.640000-04:00
1805603 PRINTING INDUSTRIES OF AMERICA, INC. 906a2a8d-25e3-4545-afd0-e2b75957bd59 Q1 PRINTING INDUSTRIES OF AMERICA, INC. 32203 PRINTING INDUSTRIES OF AMERICA INC 2016 first_quarter PHA Pharmaceutical Printed Literature Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Labor Relations Board (NLRB),Occupational Safety & Health Administration (OSHA),Securities & Exchange Commission (SEC),SENATE,U.S. Postal Service (USPS)   100000 0 0 2016-04-12T15:28:50.723000-04:00
1806070 AMERICAN COLLEGE OF CLINICAL PHARMACY 6ad7a8f1-b687-4c1d-8a08-961e9cb2cb8a Q1 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2016 first_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   128875 0 0 2016-04-13T11:24:52.810000-04:00
1807311 MASSACHUSETTS MEDICAL SOCIETY 16d4a9e2-91fd-48d3-9733-ab52eeb11cdf Q1 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2016 first_quarter PHA S 320 - Medical Innovation Act - NIH funding DEA - change/classification of regulations regarding partial fill of prescriptions Prescription Drug Pricing - no specific bill Direct to Consumer Advertising - no specific bill Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,State, Dept of (DOS)   90000 0 0 2016-04-14T11:16:15.737000-04:00
1807383 BROWN RUDNICK LLP 4c456778-f1d2-4b37-a365-7b98c26fda99 Q1 BROWN RUDNICK LLP 287895 HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC 2016 first_quarter PHA H.R. 471 & S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 524 relating to the prevention and treatment of opioid addiction HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-04-14T11:58:17.257000-04:00
1807389 BROWN RUDNICK LLP ba39d598-cee3-4a85-ba88-7a6a0e55a008 Q1 BROWN RUDNICK LLP 287895 PRIME THERAPEUTICS 2016 first_quarter PHA HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244, the MAC Transparency Act Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-04-14T12:02:31.053000-04:00
1807391 BROWN RUDNICK LLP 61e9a3cb-d116-4941-8bd8-0aeef0d7e09f Q1 BROWN RUDNICK LLP 287895 AMNEAL PHARMACEUTICALS 2016 first_quarter PHA Federal policy relating to abuse deterrent drug development HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-04-14T12:04:32.757000-04:00
1807392 BROWN RUDNICK LLP 7c8566cb-ac6e-4fe6-a8d8-eca91a26449a Q1 BROWN RUDNICK LLP 287895 EXELA HOLDINGS, LLC 2016 first_quarter PHA Federal policy relating to pharmaceutical pricing and FDA application review protocols Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-04-14T12:06:34.257000-04:00
1807402 BROWN RUDNICK LLP 3b99e3f7-f6f1-423b-948b-e263f0091c3f Q1 BROWN RUDNICK LLP 287895 ZYDUS PHARMACEUTICALS USA INC. 2016 first_quarter PHA Federal policy relating to pharmaceutical pricing HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-04-14T12:07:41.273000-04:00
1807476 RED+BLUE STRATEGIES 2582a572-f6cd-41ea-8e58-10433d1db351 Q1 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2016 first_quarter PHA National Defense Authorization Act of FY 2017 - Work to ensure that the current treatment of mail order for retired and active military personnel and their families remains constant in the pending Authorization bill. The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction. The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies. FDA's March 31, 2016 biosimilar labeling guidance and additional work regarding biosimilars. Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Issues related to mail order coverage for Medicare, Medicaid, Exchanges, Tricare and other programs. Issues related to the pricing of prescription medications. Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. Issues related to the treatment of pharmacy benefit managers in federal programs. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Issues related to access and affordability for prescription medications for both government and private sector benefit programs. H.R. 1735 - National Defense Authorization Act for Fiscal Year 2016 - issues related to prescription drug coverage options for retired and active military personnel. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-04-14T12:51:48.827000-04:00
1807530 RED+BLUE STRATEGIES bda1c18a-912d-49ac-9203-32a121bcc6e6 Q1 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2016 first_quarter PHA The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction. The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies. FDA's March 31, 2016 biosimilar labeling guidance and additional work regarding biosimilars. Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies. CCIIO issuer letter and additional guidance and regulations focused on programs in the Exchanges that impact coverage and access to prescription medications and pharmacy networks. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies. CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. Issues related to pricing and acces… Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-04-14T13:15:39.937000-04:00
1807600 RED+BLUE STRATEGIES 8bedf915-8aac-4f07-a722-1921d96026c7 Q1 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2016 first_quarter PHA S. 524 - The Comprehensive Addiction and Recovery Act - supporting efforts to fight opioid abuse in the United States. Work focused on the inclusion of "lock in" programs in the Medicare program to prevent and protect seniors from opioid addiction. S.185 - The Promise for Antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public. S. 2153 - Provider Payment Sunshine Act - policies supporting the inclusion of all prescribers to the Open Payments program. Legislative and regulatory issues surrounding unique device identifiers (UDI) being addressed by CMS, FDA and ONC. Advancing provisions to highlight Antibiotic Innovation and combating prescription drug abuse in the President's FY 2017 budget. Supporting policies to maintain the integrity of laws regarding compounding of certain medications. Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-04-14T13:41:12.660000-04:00
1807609 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 4c2c33b6-75db-4a28-aa02-c3c0113d4af8 Q1 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2016 first_quarter PHA Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding. Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   70000 0 0 2016-04-14T13:44:19.660000-04:00
1807895 KOUNTOUPES DENHAM CARR & REID, LLC 587576ff-5a14-47ca-87f3-f458b728406b Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2016 first_quarter PHA Policy matters related to generic pharmaceuticals and biosimilars including naming, labeling, access and interchangeability and changes to the Risk Evaluation and Mitigation Strategies (REMS) program, H.R.2841, FAST Generics Act of 2015. Issues related to House Energy and Commerce Committee's draft on H. R. 6, 21st Century Cures Act and the Senate Health, Education, Labor and Pensions Committee Initiative for Healthier Americans. Affordability and pricing of pharmaceuticals. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 60000   0 0 2016-04-14T15:14:23.153000-04:00
1807936 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 1f75c68f-fcf1-40c9-a148-5d95408abf12 Q1 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2016 first_quarter PHA H.R. 244 - MAC Transparency Act of 2015; Congressional Oversight of 340 B Program; S. 1406 - Saving Access to Compounding Medications for Special Needs Patients Act; Direct and Indirect Remuneration fees (DIR); Issues related to FDA implementation of The Drug Quality and Security Act related to compounding Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE   410000 0 0 2016-04-14T15:38:17.923000-04:00
1807988 COREWELL HEALTH f8102a82-bec7-4ff1-bdd4-7e0107f33425 Q1 COREWELL HEALTH 298455 COREWELL HEALTH 2016 first_quarter PHA RIN-0906-AB08 - Health Resources and Services Administration; 340B Drug Pricing Program Omnibus Guidelines; Submitted comments. Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   24000 0 0 2016-04-14T16:00:21.177000-04:00
1808058 RED+BLUE STRATEGIES 6af77c60-c1b8-4d63-a464-4e016b2ba46e Q1 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2016 first_quarter PHA Issues related to stemming the opioid epidemic in America and solutions developed by BCBSMA to combat abuse. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-04-14T16:21:45.960000-04:00
1808094 APOTEX CORP. 9a5dd130-2e57-44c3-a99d-43de978a5cf9 Q1 APOTEX CORP. 310973 APOTEX CORP. 2016 first_quarter PHA H.R. 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S. 2615, the Increasing Competition in Pharmaceuticals Act, provisions relating to priority review vouchers for and expedited approval of certain generic drug applications, and Risk Evaluation and Mitigation (REMS) programs; Federal policy relating to requirements for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; S. 131, The FAIR Generics Act, provisions relating to market blockages caused by "parked" 180 day exclusivity period; Federal policy relating to the Implementation of Public Law 112-144, The Food and Drug Administration Safety and Innovation Act, Title 3, Fees Relating to Generic Drugs; and Federal policy relating to generic drug prices. HOUSE OF REPRESENTATIVES,SENATE   130000 0 0 2016-04-14T16:41:20.290000-04:00
1808105 RED+BLUE STRATEGIES 8043822d-89e5-40ae-a031-c2086577e96e Q1 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2016 first_quarter PHA FDA's March 31, 2016 Biosimilars Labeling Guidance. Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-04-14T16:42:24.337000-04:00
1808436 ACADEMY OF MANAGED CARE PHARMACY 5cbe6bf3-f780-4c22-ba0c-f4bb0fd67117 Q1 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2016 first_quarter PHA Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   159000 0 0 2016-04-15T11:02:53.540000-04:00
1808606 CAPITOL HILL CONSULTING GROUP 810dbd18-6552-4419-bb94-1e4234abb58b Q1 CAPITOL HILL CONSULTING GROUP 72053 PURDUE PHARMA LLP 2016 first_quarter PHA Controlled Drug Substances Act (21 USC 13) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-04-15T12:00:03.030000-04:00
1808767 CAPITOL HILL CONSULTING GROUP 14f8ec1d-f540-432b-afb5-e736e62376b7 Q1 CAPITOL HILL CONSULTING GROUP 72053 ENDO PHARMACEUTICALS 2016 first_quarter PHA Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825 HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-04-15T13:11:20.730000-04:00
1808779 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 8c8474a4-b5ee-4c36-b45a-96c6bee6a528 Q1 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2016 first_quarter PHA Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953); 21st Century Cures (H.R. 6); Importation of Prescription Drugs (S. 122, H.R. 2228) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   314000 0 0 2016-04-15T13:15:31.480000-04:00
1809553 ANIMAL HEALTH INSTITUTE 8090c317-6050-4132-a8a8-76ebbcb02aaf Q1 ANIMAL HEALTH INSTITUTE 4037 ANIMAL HEALTH INSTITUTE 2016 first_quarter PHA Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions from Environmental Assessments for animal health products. HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2016-04-16T09:37:40.040000-04:00
1809623 AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 1cba34c4-d17b-4bc3-b140-767e91523431 Q1 AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 1967 AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 2016 first_quarter PHA H.R.2298-Medicare Patient Safety and Drug Abuse Prevention Act S.1913-Stopping Medication Abuse and Protecting Seniors Act of 2015 HOUSE OF REPRESENTATIVES,SENATE   661366 0 0 2016-04-16T17:06:51.847000-04:00
1809967 ELI LILLY AND COMPANY fb04bd9c-e3df-4f2b-a2ad-b740c2f5bb3f Q1 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2016 first_quarter PHA Hospital discounts; 340B Program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1250000 0 0 2016-04-18T08:44:56.283000-04:00
1810102 WILLIAMS AND JENSEN, PLLC 8d033662-8c97-4e45-a113-f98267ac7906 Q1 WILLIAMS AND JENSEN, PLLC 41454 FAGRON NORTH AMERICA 2016 first_quarter PHA Issues related to Drug Quality and Security Act (DQSA) and Pharmacy compounding. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-04-18T09:38:44.587000-04:00
1810293 CLOAKROOM ADVISORS LLC 80e67964-c405-4ea1-86dd-28c2dce95ba9 Q1 CLOAKROOM ADVISORS LLC 401103204 LINDEN CARE LLC 2016 first_quarter PHA Congressional delegation outreach and education on issues related to speciality pharmacies HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-04-18T10:42:24.063000-04:00
1810498 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 19d46aa8-c889-4285-b923-1d176dffb620 Q1 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2016 first_quarter PHA Any language supporting the expanded use of virtual care/telemedicine, including HR 2799 supporting changes in definitions to expand the use of telemedicine. HOUSE OF REPRESENTATIVES,SENATE   54115 0 0 2016-04-18T11:46:20.873000-04:00
1810507 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 5fc053d9-04e3-4e97-960f-9244c032f558 Q1 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31348 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2016 first_quarter PHA Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),General Services Administration (GSA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE   696470 0 0 2016-04-18T11:47:35.420000-04:00
1810811 RUBICON ADVISORS, LLC 6417723f-06ac-45a7-a45c-5b85cc784d9e 1T RUBICON ADVISORS, LLC 315091 CIPLA USA, INC. 2016 first_quarter PHA Food and Drug Administration, Generic Drug User Fees HOUSE OF REPRESENTATIVES,SENATE 45000   0 1 2016-04-18T13:00:58.647000-04:00
1810872 POWERS PYLES SUTTER & VERVILLE, P.C. a150b011-0910-4043-a912-19d9c4974c26 Q1 POWERS PYLES SUTTER & VERVILLE, P.C. 32008 340B HEALTH 2016 first_quarter PHA Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3) funding of the Health Resources and Services Administration (HRSA)under the Labor Health & Human Services & Education appropriations bills. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-04-18T13:20:03.853000-04:00
1811002 RUBICON ADVISORS, LLC 9383f4f3-1ec5-422d-b436-690f34ea36a1 Q1 RUBICON ADVISORS, LLC 315091 TEVA PHARMACEUTICALS USA 2016 first_quarter PHA 21st Century Cures Act HOUSE OF REPRESENTATIVES,SENATE 105000   0 0 2016-04-18T13:57:10.480000-04:00
1811010 RUBICON ADVISORS, LLC e2459f3b-f11b-4955-b562-1a60b478a3bd Q1 RUBICON ADVISORS, LLC 315091 OFFICE OF GOVERNOR NATHAN DEAL 2016 first_quarter PHA Pharmaceuticals HR 707, Restoration of America's Wire Act HOUSE OF REPRESENTATIVES,SENATE 43750   0 0 2016-04-18T13:59:13.933000-04:00
1811018 NOVO NORDISK INC. d2481333-7aef-4487-95aa-cd55039ad104 Q1 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2016 first_quarter PHA P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations     910000 0 0 2016-04-18T14:00:17.933000-04:00
1811029 RUBICON ADVISORS, LLC 3b61609e-6071-4941-989b-fdda67e88149 Q1 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2016 first_quarter PHA Pharmaceuticals HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-04-18T14:05:36.793000-04:00
1811033 RUBICON ADVISORS, LLC a0d66e1a-24c3-426e-973d-911e968082f4 Q1 RUBICON ADVISORS, LLC 315091 ALLIANCE TO PREVENT THE ABUSE OF MEDICINES 2016 first_quarter PHA Prescription drug abuse policy HOUSE OF REPRESENTATIVES,SENATE 52500   0 0 2016-04-18T14:06:40.420000-04:00
1811038 RUBICON ADVISORS, LLC f32c1074-f07f-4b95-ae11-5d8a2ccfbf15 Q1 RUBICON ADVISORS, LLC 315091 COLLEGE OF AMERICAN PATHOLOGISTS 2016 first_quarter PHA Physician Payment Rates, Electronic Health Records Incentives program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-04-18T14:08:46.843000-04:00
1811041 RUBICON ADVISORS, LLC db6a4198-6c22-40b9-b2d4-3a8785afc0b6 Q1 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2016 first_quarter PHA Food and Drug Administration, Generic Drug User Fees HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2016-04-18T14:09:52.827000-04:00
1811128 HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC 5752e426-29ac-4bc3-b4ab-03beb5b9f10f Q1 HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC 17966 ELI LILLY AND COMPANY 2016 first_quarter PHA Issues relating to prescription drug prices. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-04-18T14:23:55.797000-04:00
1811244 BLUECROSS BLUESHIELD OF TENNESSEE 2ee935d5-034b-4463-bbe7-2d74b13d31d0 Q1 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2016 first_quarter PHA General Pharmacy Issues; HR6, 21st Century Cures; opioid abuse; specialty drug pricing Equal Employment Opportunity Commission (EEOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2016-04-18T14:47:23.690000-04:00
1811277 AMERICAN VETERINARY MEDICAL ASSOCIATION 59ce7d76-0b14-44eb-a5c5-0a57e05b4e80 Q1 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2016 first_quarter PHA Discussion with Congressional staff regarding the use of antimicrobials in food-producing animals, particularly with respect to H.R. 1552 (Preservation of Antibiotics for Medical Treatment Act S.621 (Preventing Antibiotics Resistance Act), and FDA's strategy (GRI #209 and VFD Rule) Discussion with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230 Inquiries to and discussions with, Congressional staff on veterinary pet prescriptions, particularly regarding our opposition to H.R. 3174/S. 1200 - The Fairness to Pet Owners Act Discussions with DEA regarding use of controlled substances by veterinary practitioners. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE   200000 0 0 2016-04-18T14:53:51.690000-04:00
1811492 MERCURY PUBLIC AFFAIRS, LLC 41e2a128-2b5c-48a9-b12d-60b2791a6762 Q1 MERCURY PUBLIC AFFAIRS, LLC 70175 KALISPELL REGIONAL HEALTHCARE 2016 first_quarter PHA Veteran pharmacy issues and polices Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2016-04-18T15:31:24.303000-04:00
1811516 EMPIRE CONSULTING GROUP 1f54cde5-24e7-4433-9d6b-a727e5ce3e7a Q1 EMPIRE CONSULTING GROUP 400703105 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2016 first_quarter PHA Issues relating to Medicare Parts D and D; prescription drug costs/pricing;and 340 B drug pricing program. HOUSE OF REPRESENTATIVES 40000   0 0 2016-04-18T15:38:56.430000-04:00
1811593 ASSOCIATION OF NATIONAL ADVERTISERS, INC. efae68cb-98f6-49cf-870e-ccae923a5dfb Q1 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2016 first_quarter PHA Proposals relating to the regulation of direct to consumer prescription drug advertising H.R. 4565, Responsibility in Drug Advertising Act of 2016, to prohibit for three years after FDA approval direct to consumer prescription drug advertising Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE   460000 0 0 2016-04-18T15:48:18.870000-04:00
1811900 CORNERSTONE GOVERNMENT AFFAIRS, INC. dfb9881d-421e-437d-9893-0aad7cc76cad Q1 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 CHILDREN'S NATIONAL MEDICAL CENTER 2016 first_quarter PHA Representation on health-related issues including reimbursement, research, public-health & clinical care Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2016-04-18T16:40:37.187000-04:00
1812189 HIGHMARK, INC. e7e1b47f-1908-4be4-a1e4-f426cc811c4f Q1 HIGHMARK, INC. 18238 HIGHMARK INC 2016 first_quarter PHA Opioid Abuse; Prescription Drugs; Specialty Drugs HOUSE OF REPRESENTATIVES,SENATE   170000 0 0 2016-04-18T17:29:59.960000-04:00
1812305 THORSEN FRENCH ADVOCACY LLC 11938c82-3aad-45c4-9ebf-1bf5d2566cb2 1T THORSEN FRENCH ADVOCACY LLC 400599826 ASTRAZENECA PHARMACEUTICALS LP 2016 first_quarter PHA Issues related to access to pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE     0 1 2016-04-18T17:44:19.790000-04:00
1812398 THORSEN FRENCH ADVOCACY LLC ff27060c-1b30-4659-9fb0-badb1a2db81a Q1 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2016 first_quarter PHA General issues related to prescription drug abuse. Issues related to pharmaceutical market value. S.483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015. H.R.471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015. S. 524: Comprehensive Addiction and Recovery Act of 2015. H.R. 953: Comprehensive Addiction and Recovery Act of 2015. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-04-18T18:01:05.823000-04:00
1812428 THORSEN FRENCH ADVOCACY LLC 599142e9-832a-48af-b36a-c7be41c8b2de Q1 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2016 first_quarter PHA Issues related to pharmaceutical market value. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-04-18T18:06:37.980000-04:00
1812463 GILEAD SCIENCES, INC. e5ffe25e-d235-4283-844d-bbce90b502a4 Q1 GILEAD SCIENCES, INC. 287177 GILEAD SCIENCES INC 2016 first_quarter PHA Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; Issues related to coverage and reimbursement of pharmaceuticals; Issues related to Medicare, Medicaid and Affordable Care Act implementation; and FDA issues and 340B. Commerce, Dept of (DOC),Defense, Dept of (DOD),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Veterans Affairs, Dept of (VA)   980000 0 0 2016-04-18T18:12:02-04:00
1812656 CAPVIEW ASSOCIATES LLC (DBA CAPVIEW STRATEGIES) ba06b247-127f-4448-af16-4ce268db662e Q1 CAPVIEW ASSOCIATES LLC (DBA CAPVIEW STRATEGIES) 401103546 PFIZER INC. 2016 first_quarter PHA Issues related to the value of pharmaceuticals including developing sustainable models that support innovation. Centers For Medicare and Medicaid Services (CMS),Medicare Payment Advisory Commission (MedPAC) 50000   0 0 2016-04-18T21:15:30.247000-04:00
1812678 WEST FRONT STRATEGIES LLC f10308fc-be8a-4102-b1bb-95603e21560b Q1 WEST FRONT STRATEGIES LLC 401103493 WALGREEN CO. 2016 first_quarter PHA Pharmacy and Medically Underserved Areas Enhancement Act (S. 314 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas; Comprehensive Addiction and Recovery Act of 2016 (S. 524). HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-04-18T21:30:45.547000-04:00
1812889 WINNING STRATEGIES WASHINGTON d7f26584-6777-440b-a045-18e088c46637 Q1 WINNING STRATEGIES WASHINGTON 50796 KALEO 2016 first_quarter PHA Pharmaceutical drug development, Reducing opiod overdose deaths and S. 707 HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-04-19T01:00:48.360000-04:00
1813282 THE D MAJOR GROUP 95ad7956-fedf-4b09-a2e8-838f6f2a8155 Q1 THE D MAJOR GROUP 401103162 CVS CAREMARK 2016 first_quarter PHA Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-04-19T09:01:12.140000-04:00
1813576 GREATER NEW YORK HOSPITAL ASSOCIATION dbfa468c-a729-46f9-b440-fae4080956e7 Q1 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2016 first_quarter PHA Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases and support draft reform legislation; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting "any willing pharmacy" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524-0002 - comments, Administration and Capitol Hill meetings on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments and Capitol Hill meetings on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose; 21st Century Cures Act (H.R.6) - support; proposed amendments to 340b program (not ultimately included in H.R.6) - oppose; provide comments on proposed 340b omnibus guidance… Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office   320000 0 0 2016-04-19T10:13:37.070000-04:00
1813611 FOOD MARKETPLACE INC. 5ae8833e-45de-42f9-9eea-de2231859864 Q1 FOOD MARKETPLACE INC. 15097 FOOD MARKETPLACE INC 2016 first_quarter PHA H.R. 1270 / S. 620 - Restore Access to Medication Act H.R. 592 / S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 2029 - Consolidated Appropriations Act, House Amendments 1 and 2 to Senate Amendment published as Rules Committee Prints 114-39 and 114-40 H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015 H.R. 793/S. 1190 - the Ensuring Seniors Access to Local Pharmacies Act Health Savings Act of 2016 - H.R.4469/S.2499 HOUSE OF REPRESENTATIVES,SENATE   140000 0 0 2016-04-19T10:19:03.710000-04:00
1813818 ARNALL GOLDEN GREGORY, LLP 0c037a8d-ae12-4b3d-a940-e15632243966 Q1 ARNALL GOLDEN GREGORY, LLP 400713137 PHARMA AND BIOPHARMA OUTSOURCING ASSOCIATION 2016 first_quarter PHA FDA issues; Generic Drug Free User Act issues; small business relief legislation HOUSE OF REPRESENTATIVES,SENATE     0 0 2016-04-19T10:40:36.057000-04:00
1813926 MEHLMAN CONSULTING, INC. d62b4867-2bf3-4090-b010-c1a21f98826b Q1 MEHLMAN CONSULTING, INC. 284950 WALMART INC 2016 first_quarter PHA Implementation of Medicare Part D and the Affordable Care Act. HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2016-04-19T10:51:51.480000-04:00
1814000 DENTONS US LLP 12e47cb8-dd30-4d93-b94d-b784fdcaf5a0 Q1 DENTONS US LLP 36105 PURDUE PHARMA 2016 first_quarter PHA U.S. and Canadian regulatory policies regarding prescription drug abuse HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-04-19T11:00:55.653000-04:00
1814390 AMERICAN PHARMACISTS ASSOCIATION b4ab0eb7-9d20-46ac-a33e-9ba5a57a2892 Q1 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2016 first_quarter PHA Reimbursement of pharmacist services - HR592/S314 Transitions of care Risk evaluation and mitigation services Track and trace/supply chain Health information technology Immunizations Compounding Tele-medicine Quality rating AMP FULs/MAC pricing Biosimiliars Drug importation Generics labeling Pharmacy Benefit Managers Preferred pharmacy network - HR793 Electronic labeling 21st century cures - HR6 Drug Disposal/Management Drug Prices Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   30000 0 0 2016-04-19T11:51:51.910000-04:00
1814681 WALTER CONSULTING a3d2e4ba-5be7-49d5-a124-c9f302dd3a2c Q1 WALTER CONSULTING 301697 AMERISOURCEBERGEN CORPORATION 2016 first_quarter PHA H.R. 471, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483, The Regulatory Transparency, Patient Access and Effective Drug Enforcement Act HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-04-19T12:23:09.600000-04:00
1814683 INDEPENDENT PHARMACY COOPERATIVE de85661c-f0a1-491b-aaed-a1817c6da719 Q1 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2016 first_quarter PHA H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas. H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas. S.524 Comprehensive Addiction and Recovery Act of 2015. IPC is against as currently written. HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2016-04-19T12:23:11.037000-04:00
1814841 JOHNS HOPKINS UNIVERSITY 13c4c552-3c07-422d-ae60-9267db8d9505 Q1 JOHNS HOPKINS UNIVERSITY 20664 JOHNS HOPKINS UNIVERSITY 2016 first_quarter PHA Pharmaceutical drug price increases; 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Defense Advanced Research Projects Agency (DARPA),Energy, Dept of,HOUSE OF REPRESENTATIVES,SENATE   110000 0 0 2016-04-19T12:36:10.383000-04:00
1815154 FOLEY & LARDNER LLP b7139681-1588-4b4c-8121-cd4cf273e326 Q1 FOLEY & LARDNER LLP 15042 PAR PHARMACEUTICAL 2016 first_quarter PHA FDA issues HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-04-19T13:14:13.327000-04:00
1815476 UNIVERSITY OF IOWA 915a2330-549e-47e3-955f-1d2d4fda58d7 Q1 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2016 first_quarter PHA Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)   86662 0 0 2016-04-19T13:47:17.157000-04:00
1815613 CHAMBER HILL STRATEGIES f760cf86-870f-44f4-8ed0-f0d9492016b5 Q1 CHAMBER HILL STRATEGIES 400645947 AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL) 2016 first_quarter PHA Implementation issues related to P.L. 113-54, the Drug Quality and Security Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-04-19T14:02:54.800000-04:00
1816356 HANCE SCARBOROUGH 0a29e83e-4b1c-47c9-b8ec-74419f54331d Q1 HANCE SCARBOROUGH 17443 ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS 2016 first_quarter PHA Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs. HOUSE OF REPRESENTATIVES,SENATE     0 0 2016-04-19T15:10:42.920000-04:00
1816895 OREGON HEALTH & SCIENCE UNIVERSITY eb091650-2fc3-4e6e-8c44-c6569b13268b Q1 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2016 first_quarter PHA 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2016-04-19T15:52:32.423000-04:00
1816992 UNIVERSITY OF PITTSBURGH MEDICAL CENTER 3929b5cb-a5b2-4b0d-af64-400acaabf0b7 Q1 UNIVERSITY OF PITTSBURGH MEDICAL CENTER 32065 UNIVERSITY OF PITTSBURGH MEDICAL CENTER 2016 first_quarter PHA Urge Congress to oppose cuts to the 340B program and address the escalation in drug prices. HOUSE OF REPRESENTATIVES,SENATE   260000 0 0 2016-04-19T15:59:40.643000-04:00
1817061 COVINGTON & BURLING LLP 9563d79e-4cad-42a2-9d3c-9d7d2c24f6df Q1 COVINGTON & BURLING LLP 11195 FABRE-KRAMER PHARMACEUTICALS, INC 2016 first_quarter PHA Policy regarding demonstration of effectiveness for new drug approvals. HOUSE OF REPRESENTATIVES,SENATE     0 0 2016-04-19T16:06:40.910000-04:00
1817074 ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA MNK PHARMACEUTICALS) 889ff66a-ab5f-4a99-8473-618ae8f0fd8e Q1 ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA MNK PHARMACEUTICALS) 401095056 ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA 2016 first_quarter PHA Highly enriched to Low enriched uranium (HEU-LEU) related issues for Nuclear Medicine (no specific bill number); 21st Century CURES Act (H.R.6)Issues related to "real world" clinical evidence; Issues related to Opioid abuse and alternatives to opioids (no specific bill number). Energy, Dept of,HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE   590000 0 0 2016-04-19T16:06:44-04:00
1817115 TARPLIN, DOWNS & YOUNG, LLC dafc1fa7-2df4-43ca-9ae1-f128b8364e2a Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2016 first_quarter PHA Importation of prescription drugs (S. 122, H.R. 2228) Rx Pedigree (PL 113-54) Prescription Drug Monitoring Programs (S. 480, H.R. 1725) Prescription Drug Abuse - General issues related to Rx drug abuse (H.R. 471, S. 483, S. 524, H.R. 953) 21st Century Cures (H.R. 6) Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2016-04-19T16:10:13.207000-04:00
1817321 AMERICAN ACADEMY OF FAMILY PHYSICIANS 56c22f7d-2f35-4dbf-ac85-a343bb3da92e Q1 AMERICAN ACADEMY OF FAMILY PHYSICIANS 1342 AMERICAN ACADEMY OF FAMILY PHYSICIANS 2016 first_quarter PHA S 524/HR 953 - Comprehensive Addiction and Recovery Act: Supporting drug monitoring programs & interstate exchange of data, and opposing mandatory professional education for prescribing physicians. No Bill No.-Prescription Drug Abuse: Supporting drug monitoring programs and interstate exchange of data. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,White House Office   715182 0 0 2016-04-19T16:34:48.367000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1398.356ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API